• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

    6/27/23 2:13:31 PM ET
    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APTX alert in real time by email
    SC 13D/A 1 tm2319449-1_sc13d.htm SC 13D/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 
    Washington, D.C. 20549

     

    AMENDMENT No. 1 to

    SCHEDULE 13D 

    Under the Securities Exchange Act of 1934

     

     Aptinyx Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

     03836N103

     

    (Cusip Number)

     

     Elisha (“Terry”) P. Gould III

    One North Wacker Drive, Suite 2700,
    Chicago, Illinois 60606

    (312) 553-7890

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    June 27, 2023

     

    (Date of Event Which Requires Filing of this Statement)

      

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Partners, LLC

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      5,395,9961
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      5,395,9961
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 5,395,9961

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    8.0%2

     

    14Type of Reporting Person (See Instructions):

     

    IA

     

      

    (1) Represents shares of common stock held by the other Reporting Persons included in this Schedule 13D for which Adams Street Partners, LLC has voting and dispositive power.

    (2) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Partnership Fund – 2002 U.S. Fund, L.P. 

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      82,079
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      82,079
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 82,079

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent (1)

     

    14Type of Reporting Person (See Instructions):

     

    PN

     

      

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Partnership Fund – 2003 U.S. Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      75,336
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      75,336
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 75,336

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Partnership Fund – 2004 U.S. Fund, L.P.

     

    2 Check the Appropriate Box if a Member of a Group (See Instructions):  

    (a) x

    (b) ¨

     

    3 SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6 Citizenship or Place of Organization:  Delaware 

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      58,192
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      58,192
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 58,192

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN

     

      

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Partnership Fund - 2005 U.S. Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      81,061
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      81,061
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 81,061

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Brinson Partnership Fund – 2004 Primary Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      4,808
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      4,808
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 4,808

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

     UBS Asset Management Trust Company as Trustee of The Brinson Non-U.S. Partnership Fund Trust- 2004 Primary Fund

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Illinois

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      10,022
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      10,022
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 10,022

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    OO  

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    2004 Primary Brinson Partnership Fund Offshore Series Company Ltd.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Cayman Islands

     

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      3,227
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      3,227
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 3,227

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     
    14Type of Reporting Person (See Instructions):

     

    CO

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    The Bank Of New York Mellon as Trustee for the HP Inc. Master Trust

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Illinois

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      50,643
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      50,6431
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 50,643

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     
    14Type of Reporting Person (See Instructions):

     

    OO

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2008 Direct Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      249,791
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      249,791
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 249,791

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     
    14Type of Reporting Person (See Instructions):

     

    PN

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2009 Direct Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      216,053
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      216,053
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 216,053

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)  

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

      

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2010 Direct Fund, L.P.

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      122,728
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      122,728
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 122,728

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2011 Direct Fund LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      106,754
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      106,754
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 106,754

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN  

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2012 Direct Fund LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      691,176
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      691,176
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 691,176

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    1.0%(1) 

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2013 Direct Fund LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      522,837
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      522,837
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 522,837

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2014 Direct Fund LP

     

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a)  x

    (b)  ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      711,151
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      711,151
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 711,151

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    1.1%(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D 

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2015 Direct Venture/Growth Fund LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      504,708
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      504,708
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 504,708

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     

    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street 2016 Direct Venture/Growth Fund LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      439,714
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      439,714
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 439,714

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    Less than one percent(1) 

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 03836N103

     

     
    1Names of Reporting Persons:                  I.R.S. Identification Nos. of Above Persons (entities only):

     

    Adams Street Venture/Growth Fund VI LP

     

    2Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) x

    (b) ¨

     

    3SEC Use Only:

      

     

    4Source of Funds (See Instruction):  OO

     

     

    5Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):        ¨

      

     

    6Citizenship or Place of Organization:  Delaware

     

     

     

    Number of Shares

     Beneficially

     Owned by

     Each

     Reporting

     Person

     With

     7 Sole Voting Power:
      1,465,716
       
     8 Shared Voting Power:
      --
       
     9 Sole Dispositive Power:
      1,465,716
       
     10 Shared Dispositive Power:
      --
       
     

    11Aggregate Amount Beneficially Owned by Each Reporting Person: 1,465,716

     

     

    12Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨

     

     

    13Percent of Class Represented by Amount in Row (11):

     

    2.2%(1)

     

    14Type of Reporting Person (See Instructions):

     

    PN 

     

     

    (1) Based on the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on May 18, 2023, there were 67,715,718 shares of common stock of the Issuer outstanding as of May 15, 2023.

     

     

     

     

     

    Item 1.     Security and Issuer.

     

    This Amendment No. 1 to Schedule 13D (this “Amendment”) amends and supplements the Schedule 13D that was filed with the Securities and Exchange Commission on January 17, 2020 by the entities (each a “Reporting Person”) set forth on the cover pages of this Schedule 13D (the “Original 13D” and as amended and supplemented by this Amendment, the “Schedule 13D”). The Schedule 13D relates to the common stock (the “Common Stock”) of Aptinyx Inc., a Delaware corporation (the “Issuer” or “Registrant”).  The address of the principal executive offices of the Issuer is 909 Davis Street, Suite 600, Evanston, Illinois 60201; its telephone number is (847) 871-0377. Only those items that are hereby reported are amended; all other items reported in the Original 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Terms defined in the Original 13D are used herein as so defined.

     

    Item 2. Identity and Background.

     

    (a)       This Schedule 13D is being jointly filed by the entities set forth on the cover pages of this Schedule 13D (each a “Reporting Person”).

     

    Adams Street Partners, LLC may be deemed to beneficially own the shares of Common Stock held by each of the following Reporting Persons as the managing member of the general partner of each such Reporting Person: Adams Street Partnership Fund – 2002 U.S. Fund, L.P.; Adams Street Partnership Fund – 2003 U.S. Fund, L.P.; Adams Street Partnership Fund – 2004 U.S. Fund, L.P.; Adams Street Partnership Fund – 2005 U.S. Fund, L.P.; Brinson Partnership Fund – 2004 Primary Fund, L.P.; Adams Street 2008 Direct Fund, L.P.; Adams Street 2009 Direct Fund, L.P.; and Adams Street 2010 Direct Fund, L.P.

     

    Adams Street Partners, LLC may be deemed to beneficially own the shares held by each of the following Reporting Persons as managing member of the general partner of the general partner of each such Reporting Person: Adams Street 2011 Direct Fund LP; Adams Street 2012 Direct Fund LP; Adams Street 2013 Direct Fund LP; Adams Street 2014 Direct Fund LP; Adams Street 2015 Direct Venture/Growth Fund LP; Adams Street 2016 Direct Venture/Growth Fund LP; and Adams Street Venture/Growth Fund VI LP.

     

    Adams Street Partners, LLC may be deemed to beneficially own the shares of Common Stock held by each of the following Reporting Persons as the investment sub-adviser of each of the Reporting Persons: UBS Asset Management Trust Company, as the trustee of The Brinson Non-U.S. Partnership Fund Trust- 2004 Primary Fund; the 2004 Primary Brinson Partnership Fund Offshore Series Company Ltd.; and, The Bank Of New York Mellon as Trustee for the HP Inc. Master Trust.

     

    Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray, and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares of Common Stock held by each of the Reporting Persons. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray, and Fred Wang disclaim beneficial ownership of the shares held by each of the Reporting Persons except to the extent of their pecuniary interest therein.

     

     

     

     

    (b)       The principal business address for each Reporting Person and the individuals listed on Schedule A is One North Wacker Drive, Suite 2700, Chicago, Illinois 60606.

     

    (c)       The principal occupation of each of the persons set forth on Schedule A hereto is the venture capital and growth equity investment business. The information set forth in Schedule A hereto is incorporated herein by reference. Elisha P. Gould III is a director of the Issuer.

     

    (d)       None of the Reporting Persons, and to the best of the knowledge of the Reporting Persons, none of the individuals listed on Schedule A, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.

     

    (e)       During the last five years, none of the Reporting Persons, and to the best of the knowledge of the Reporting Persons, none of the individuals listed on Schedule A, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, each Reporting Person and to the best of the knowledge of the Reporting Persons, each individual on Schedule A, has not been and is not now subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)       Each of the Reporting Persons is a Delaware entity, except that UBS Asset Management Trust Company, the Trustee of The Brinson Non-U.S. Partnership Fund Trust-2004 Primary Fund and The Bank Of New York Mellon as Trustee for the HP Inc. Master Trust, are Illinois corporations, and 2004 Primary Brinson Partnership Fund Offshore Series Company Ltd. is a Cayman Islands corporation.

     

    Item 5. Interests in Securities of the Issuer

     

    (a,b) For information regarding beneficial ownership, see the information presented on the cover pages of this Schedule 13D.

     

    The shares of Common Stock beneficially owned by Adams Street Partners, LLC that are reported on this Schedule 13D include all of the other shares that are beneficially owned by each of the other Reporting Persons as Adams Street Partners, LLC may be deemed to beneficially own the shares held by them. Adams Street Partners, LLC disclaims beneficial ownership except to the extent of its pecuniary interest in such shares.

     

    (c) The Reporting Persons have not effected any transactions in the Common Stock of the Issuer in the last 60 days.

     

    (d) Under certain circumstances set forth in the organizational documents of the Reporting Persons, the general partner, members and limited partners of the reporting persons may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entities of which they are a partner.

     

    (e) Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 27, 2023

     

    ADAMS STREET PARTNERS, LLC

     

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President 

     

    Adams Street Partnership Fund – 2002 U.S. Fund, L.P.

     

    By: Adams Street Partners, LLC, its General Partner 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET PARTNERSHIP FUND – 2003 U.S. FUND, L.P.

     

    By: Adams Street Partners, LLC, its General Partner 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET PARTNERSHIP FUND – 2004 U.S. FUND, L.P.

     

    By: Adams Street Partners, LLC, its General Partner 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET PARTNERSHIP FUND – 2005 U.S. FUND, L.P.

     

    By: Adams Street Partners, LLC, its General Partner

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    BRINSON PARTNERSHIP FUND – 2004 Primary Fund, L.P.

     

    By: Adams Street Partners, LLC, its General Partner 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

     

     

     

    BRINSON NON-U.S. PARTNERSHIP FUND TRUST– 2004 PRIMARY FUND

     

     By: Adams Street Partners, LLC, as investment sub-adviser

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    2004 PRIMARY BRINSON PARTNERSHIP FUND OFFSHORE SERIES COMPANY LTD.

     

    By: Adams Street Partners, LLC, as investment sub-adviser 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President 

     

    THE BANK OF NEW YORK MELLON AS TRUSTEE FOR THE HP INC. MASTER TRUST

      

    By: Adams Street Partners, LLC, as investment sub-adviser 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET 2008 DIRECT FUND, L.P.

     

    By: ASP 2008 Direct Management LLC, its General Partner 

    By: Adams Street Partners, LLC, its Managing Member 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET 2009 DIRECT FUND, L.P.

     

    By: ASP 2009 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

      

    ADAMS STREET 2010 DIRECT FUND, L.P.

     

     By: ASP 2010 Direct Management LLC, its General Partner

     By: Adams Street Partners, LLC, its Managing Member

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

     

     

     

    ADAMS STREET 2011 DIRECT FUND LP

     

    By: ASP 2011 Direct Management LP, its General Partner

    By: ASP 2011 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

     Title: Executive Vice President

     

     ADAMS STREET 2012 DIRECT FUND LP

     

    By: ASP 2012 Direct Management LP, its General Partner

    By: ASP 2012 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET 2013 DIRECT FUND LP

     

    By: ASP 2013 Direct Management LP, its General Partner

    By: ASP 2013 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member 

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

      

     ADAMS STREET 2014 DIRECT FUND LP

     

    By: ASP 2014 Direct Management LP, its General Partner

    By: ASP 2014 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member

      

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET 2015 DIRECT VENTURE/GROWTH FUND LP

     

    By: ASP 2015 Direct Management LP, its General Partner

    By: ASP 2015 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member

     

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

     

     

     

    ADAMS STREET 2016 DIRECT VENTURE/GROWTH FUND LP

     

    By: ASP 2016 Direct Management LP, its General Partner

    By: ASP 2016 Direct Management LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member

      

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

    ADAMS STREET VENTURE/GROWTH FUND VI LP

     

    By: ASP VG Management VI LP, its General Partner

    By: ASP VG Management VI LLC, its General Partner

    By: Adams Street Partners, LLC, its Managing Member

      

    By: /s/ Sara Robinson Dasse  

    Name: Sara Robinson Dasse

    Title: Executive Vice President

     

     

     

     

     

     Schedule A

     

     

     

    NAME   PRINCIPAL OCCUPATION OR EMPLOYMENT  
    Thomas S. Bremner   Partner, Adams Street Partners, LLC  
    Jeffrey T. Diehl   Partner, Adams Street Partners, LLC  
    Brian Dudley   Partner, Adams Street Partners, LLC  
    Elisha P. Gould III   Partner, Adams Street Partners, LLC  
    Robin P. Murray   Partner, Adams Street Partners, LLC  
    Fred Wang   Partner, Adams Street Partners, LLC  

      

    The address of each individual listed is One North Wacker Drive, Suite 2700, Chicago, IL 60606-2823. Each of the individuals is a citizen of the United States.

     

     

     

     

     

     

    Get the next $APTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APTX

    DatePrice TargetRatingAnalyst
    4/7/2022Outperform → Mkt Perform
    William Blair
    12/20/2021$12.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $APTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

      Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi

      3/30/23 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

      NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-

      2/27/23 4:03:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang

      10/20/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic

      5/10/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)

      SC 13G/A - Aptinyx Inc. (0001674365) (Subject)

      2/9/24 5:16:02 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      6/27/23 2:13:31 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      3/16/23 4:19:28 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Financials

    Live finance-specific insights

    See more
    • Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

      Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor

      11/8/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'

      10/18/22 7:45:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

       Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the

      8/4/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aptinyx downgraded by William Blair

      William Blair downgraded Aptinyx from Outperform to Mkt Perform

      4/7/22 1:13:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aptinyx with a new price target

      SVB Leerink reiterated coverage of Aptinyx with a rating of Outperform and set a new price target of $10.00 from $12.00 previously

      12/20/21 4:47:19 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx downgraded by JP Morgan

      JP Morgan downgraded Aptinyx from Neutral to Underweight

      1/29/21 8:18:50 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    SEC Filings

    See more
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/21/23 10:52:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/18/23 5:00:17 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Aptinyx Inc.

      25-NSE - Aptinyx Inc. (0001674365) (Subject)

      7/10/23 6:04:47 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khanna Ashish

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Riedel Norbert G

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:01 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kidd Andrew

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:16:09 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care